Recent Investment Analysts’ Ratings Updates for Kiniksa Pharmaceuticals (KNSA)

A number of firms have modified their ratings and price targets on shares of Kiniksa Pharmaceuticals (NASDAQ: KNSA) recently:

  • 8/16/2019 – Kiniksa Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $12.00 price target on the stock. According to Zacks, “Kiniksa Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa Pharmaceuticals Ltd. is based in Massachusetts, United States. “
  • 8/14/2019 – Kiniksa Pharmaceuticals had its price target lowered by analysts at JMP Securities to $35.00. They now have a “market outperform” rating on the stock. They noted that the move was a valuation call. They noted that the move was a valuation call.
  • 8/14/2019 – Kiniksa Pharmaceuticals had its “buy” rating reaffirmed by analysts at Wedbush. They wrote, “Our estimated market value of the firm is $1.75B, which includes the asset value for tagraxofusp and 15% discount rate and 2% terminal growth rate. The probability of success is 66% for tagraxofusp in indications beyond BPDCN and 45% for SL-701. Assuming roughly 50.1M shares outstanding at the end of 2Q20, this leads to a 12-month price target of approximately $35 per share.””
  • 8/1/2019 – Kiniksa Pharmaceuticals was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 7/4/2019 – Kiniksa Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Kiniksa Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa Pharmaceuticals Ltd. is based in Massachusetts, United States. “

Shares of KNSA stock traded up $0.51 on Monday, reaching $10.50. 492 shares of the company’s stock traded hands, compared to its average volume of 76,332. Kiniksa Pharmaceuticals Ltd has a 12-month low of $9.08 and a 12-month high of $32.88. The company has a market capitalization of $514.74 million, a P/E ratio of -3.01 and a beta of -1.56. The business’s 50 day moving average price is $12.85 and its two-hundred day moving average price is $15.45.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.68) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.03. On average, equities research analysts expect that Kiniksa Pharmaceuticals Ltd will post -3.47 EPS for the current year.

Several hedge funds have recently modified their holdings of the company. JPMorgan Chase & Co. grew its holdings in shares of Kiniksa Pharmaceuticals by 33.1% during the second quarter. JPMorgan Chase & Co. now owns 3,832 shares of the company’s stock valued at $52,000 after buying an additional 952 shares in the last quarter. BNP Paribas Arbitrage SA boosted its position in Kiniksa Pharmaceuticals by 1,131.7% during the first quarter. BNP Paribas Arbitrage SA now owns 2,685 shares of the company’s stock valued at $48,000 after purchasing an additional 2,467 shares during the last quarter. Bank of New York Mellon Corp boosted its position in Kiniksa Pharmaceuticals by 20.5% during the fourth quarter. Bank of New York Mellon Corp now owns 20,570 shares of the company’s stock valued at $578,000 after purchasing an additional 3,499 shares during the last quarter. Parametric Portfolio Associates LLC boosted its position in Kiniksa Pharmaceuticals by 17.9% during the second quarter. Parametric Portfolio Associates LLC now owns 31,595 shares of the company’s stock valued at $428,000 after purchasing an additional 4,787 shares during the last quarter. Finally, Rhumbline Advisers boosted its position in Kiniksa Pharmaceuticals by 61.2% during the first quarter. Rhumbline Advisers now owns 12,811 shares of the company’s stock valued at $231,000 after purchasing an additional 4,862 shares during the last quarter. Institutional investors and hedge funds own 30.15% of the company’s stock.

Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis.

Read More: Death Cross

Receive News & Ratings for Kiniksa Pharmaceuticals Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals Ltd and related companies with MarketBeat.com's FREE daily email newsletter.